Skip to main content

Advertisement

SpringerLink
Log in

The anti-tumoral role of Hesperidin and Aprepitant on prostate cancer cells through redox modifications

  • Research
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Prostate cancer is the second prevalent cancer in men. While the anti-cancer effect of Hesperidin and (Aprepitant) AP on prostate cancer cells is well documented, their combined effect and their mechanism of action are not fully investigated. Therefore, this study aimed to investigate the anti-cancer effects of Hesperidin and AP alone and in combination on prostate cancer cells. PC3 and LNCaP cell lines were treated with Hesperidin and AP alone and in combination. The Resazurin test was used for assessing cell viability. The ROS (reactive oxygen Species) level, P53, P21, Bcl-2, and Survivin gene expression were assessed. Also, a trypan blue assay was done. Hesperidin and AP reduced cell viability and increased apoptosis in PC3 and LNCaP cells. The ROS level reduced after treating the PC3 and LNCaP cells with AP with or without Hesperidin. P53 and P21 gene expression increased after treatment with Hesperidin with or without AP compared to the untreated group in the PC3 cell line. Bcl-2 and Survivin gene expression decreased with AP with or without Hesperidin in the PC3 and LNCaP cells. The current study showed the synergic anti-cancer effect of Hesperidin and AP in both PC3 and LNCaP cell lines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The authors of this article will share all the data underlying the findings of their manuscripts with other researchers. Therefore, I hereby declare the statement of “availability” for the data used in this manuscript. researchers can communicate with the first author and the corresponding authors for the data by email.

References

  • Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9(6):400–414

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Arbab IA, Looi CY, Abdul AB, Cheah FK, Wong WF, Sukari MA et al (2012) Dentatin induces apoptosis in prostate cancer cells via Bcl-2, Bcl-xL, Survivin downregulation, caspase-9,-3/7 activation, and NF-κB inhibition. Evid Based Complement Alternat Med 2012:856029

  • Barani M, Sabir F, Rahdar A, Arshad R, Kyzas GZ (2020) Nanotreatment and nanodiagnosis of prostate cancer: recent updates. Nanomaterials (Basel) 10(9):1696

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 68(6):394–424

    PubMed  Google Scholar 

  • Cussenot O, Villette J, Valeri A, Cariou G, Desgrandchamps F, Cortesse A et al (1996) Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155(4):1340–1343

    Article  CAS  PubMed  Google Scholar 

  • de Oliveira JMPF, Santos C, Fernandes E (2020) Therapeutic potential of hesperidin and its aglycone hesperetin: Cell cycle regulation and apoptosis induction in cancer models. Phytomedicine 73:152887

    Article  Google Scholar 

  • Ebrahimi S, Mirzavi F, Aghaee-Bakhtiari SH (1869) Hashemy SI (2022) SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant. Biochimica et Biophysica Acta (BBA)-Mol Cell Res 5:119221

    Google Scholar 

  • Esteban F, Muñoz M, Gonzalez-Moles M, Rosso M (2006) A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25(1):137–145

    Article  CAS  PubMed  Google Scholar 

  • Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M et al (2018) Global cancer observatory: cancer today. Lyon, France. Int Agency Res Cancer 3(20):2019

    Google Scholar 

  • Ghahremanloo A, Javid H, Afshari AR, Hashemy SI (2021) Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells. BioMed Res Int 2021:Article ID 1383878

  • Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1):11–19

    Article  CAS  PubMed  Google Scholar 

  • Javid H, Asadi J, Zahedi Avval F, Afshari AR, Hashemy SI (2020) The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways. Mol Biol Rep 47(3):2253–2263

    Article  CAS  PubMed  Google Scholar 

  • Javid H, Ghahremanloo A, Afshari AR, Salek R, Hashemy SI (2022a) The Emerging Role of Neurokinin-1 Receptor Blockade Using Aprepitant in the Redox System of Esophageal Squamous Cell Carcinoma. Int J Pept Res Ther 28(3):1–13

    Article  Google Scholar 

  • Javid H, Hashemy SI, Heidari MF, Esparham A, Gorgani-Firuzjaee S (2022b) The anticancer role of cerium oxide nanoparticles by inducing antioxidant activity in esophageal cancer and cancer stem-like ESCC spheres. BioMed Res Int 2022:3268197

  • Kabala-Dzik A, Rzepecka-Stojko A, Kubina R, Iriti M, Wojtyczka RD, Buszman E et al (2018) Flavonoids, bioactive components of propolis, exhibit cytotoxic activity and induce cell cycle arrest and apoptosis in human breast cancer cells MDA-MB-231 and MCF-7: A comparative study. Cell Mol Biol (Noisy-le-grand) 25;64(8):1–10

  • Katzenwadel A, Wolf P (2015) Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Lett 367(1):12–17

    Article  CAS  PubMed  Google Scholar 

  • Kim J, Kim J, Bae J-S (2016) ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp Mol Med 48(11):e269-e

    Article  Google Scholar 

  • Kirkin V, Joos S, Zörnig M (2004) The role of Bcl-2 family members in tumorigenesis. Biochimica et Biophysica Acta (BBA)-Mol Cell Res 1644(2–3):229–49

    Article  CAS  Google Scholar 

  • Lee CJ, Wilson L, Jordan MA, Nguyen V, Tang J, Smiyun G (2010) Hesperidin suppressed proliferations of both Human breast cancer and androgen-dependent prostate cancer cells. Phytother Res 24(S1):S15–S19

    Article  PubMed  Google Scholar 

  • Lee D-H, Park K-I, Park H-S, Kang S-R, Nagappan A, Kim J-A, et al. (2012) Flavonoids isolated from Korea Citrus aurantium L. induce G2/M phase arrest and apoptosis in human gastric cancer AGS cells. Evid Based Complement Alternat Med. 2012

  • Li C, Schluesener H (2017) Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr 57(3):613–631

    Article  CAS  PubMed  Google Scholar 

  • Moloney JN, Cotter TG (eds) (2018) ROS signalling in the biology of cancer. Semin Cell Dev Biol 80:50–64

  • Muller PA, Vousden KH, Norman JC (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192(2):209–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Muñoz M, Coveñas R (2020) The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers 12(9):2682

    Article  PubMed  PubMed Central  Google Scholar 

  • Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28(2):187–193

    Article  PubMed  Google Scholar 

  • Nakazawa M, Paller C, Kyprianou N (2017) Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep 19(2):1–12

    Article  Google Scholar 

  • Ning L, Zhao W, Gao H, Wu Y (2020) Hesperidin induces anticancer effects on human prostate cancer cells via ROS-mediated necrosis like cell death. J BUON 25(6):2629–2634

    PubMed  Google Scholar 

  • O’brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267(17):5421–6

    Article  PubMed  Google Scholar 

  • Obata K, Shimo T, Okui T, Matsumoto K, Takada H, Takabatake K et al (2016) Tachykinin receptor 3 distribution in human oral squamous cell carcinoma. Anticancer Res 36(12):6335–6341

    Article  CAS  PubMed  Google Scholar 

  • O’Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W et al (2015) Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget 6(28):26029

    Article  PubMed  PubMed Central  Google Scholar 

  • Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 47(19):6645–6653

    Article  CAS  PubMed  Google Scholar 

  • Pandey P, Khan F (2021) A mechanistic review of the anticancer potential of hesperidin, a natural flavonoid from citrus fruits. Nutr Res 92:21–31

    Article  CAS  PubMed  Google Scholar 

  • Rydzewska LH, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T et al (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88–101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tanwar B, Modgil R (2012) Flavonoids: Dietary occurrence and health benefits. Spatula Dd 2(1):59–68

    Article  Google Scholar 

  • Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr (1998) NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281(5383):1680–1683

    Article  CAS  PubMed  Google Scholar 

  • Zhang Y, Liu X, Ruan J, Zhuang X, Zhang X, Li Z (2020) Phytochemicals of garlic: Promising candidates for cancer therapy. Biomed Pharmacother 123:109730

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran

    Sanaz Akbari & Reza Assaran Darban

  2. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Hossein Javid & Seyed Isaac Hashemy

  3. Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran

    Hossein Javid

  4. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Hossein Javid & Seyed Isaac Hashemy

  5. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Ali Esparham

Authors
  1. Sanaz Akbari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Assaran Darban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Javid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ali Esparham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seyed Isaac Hashemy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Sanaz Akbari, Seyed Isaac Hashemy, Reza Assaran Darban and Hossein Javid conceived and planned the experiments and was involved in the management of the cases. Sanaz Akbari, Hossein Javid, and Ali Esparham carried out the experiments. Hossein Javid analyzed the data. Sanaz Akbari, Reza Assaran Darban, Hossein Javid, Ali Esparham wrote the initial manuscript. Seyed Isaac Hashemy assisted in writing the revised manuscript. All authors approved the final version for submission. The authors declare that all data were generated in-house and that no paper mill was used.

Corresponding author

Correspondence to Seyed Isaac Hashemy.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

For this kind of study, ethical approval is not necessary.

Conflicts of interest

The authors declare they have no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akbari, S., Assaran Darban, R., Javid, H. et al. The anti-tumoral role of Hesperidin and Aprepitant on prostate cancer cells through redox modifications. Naunyn-Schmiedeberg's Arch Pharmacol 396, 3559–3567 (2023). https://doi.org/10.1007/s00210-023-02551-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-023-02551-0

Keywords

Search

Navigation